Art

J-GLOBAL ID：201902254515075410   Reference number：19A1249041

Adjustment of Conditions for Combining Oxybutynin Transdermal Patch with Heparinoid Cream in Mice by Analyzing Blood Concentrations of Oxybutynin Hydrochloride

オキシブチニン塩酸塩の血中濃度を分析することによるマウスにおけるオキシブチニン経皮パッチとヘパリノイドクリームとの併用に対する条件の調整

Author (6)： Murakami Yoshihito (Sunai Pharmacy Co., Ltd.) ,  Murakami Yoshihito (Laboratory of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, Suzuka University of Medical Science) ,  Sekijima Hidehisa (Department of Pharmaceutical Sciences, Suzuka University of Medical Science) ,  Fujisawa Yutaka (Department of Pharmaceutical Sciences, Suzuka University of Medical Science) ,  Ooi Kazuya (Laboratory of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, Suzuka University of Medical Science) ,  Ooi Kazuya (Department of Pharmaceutical Sciences, Suzuka University of Medical Science)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 42  Issue： 4  Page： 586-593(J-STAGE)  Publication year： 2019 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： mouse(animal) ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1249041&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (8)： pharmacokinetics ,  oxybutynin transdermal patch ,  dry skin ,  heparinoid cream ,  pharmacokinetics ,  oxybutynin transdermal patch ,  dry skin ,  heparinoid cream

JST classification (2)： Basic dermatology  (GF01020Y) ,  Basic biopharmacy  (GY01021U)

Substance index (1)： Oxybutynin hydrochloride

Reference (41)：

• 1) Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP, American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J. Urol., 188 (Suppl.), 2455-2463 (2012).
• 2) Lee UJ, Scott VC, Rashid R, Behniwal A, Wein AJ, Maliski SL, Anger JT. Defining and managing overactive bladder: disagreement among the experts. Urology, 81, 257-262 (2013).
• 3) Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int., 96, 1314-1318 (2005).
• 4) Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J. Am. Geriatr. Soc., 59, 1465-1470 (2011).
• 5) Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J. Urol., 193, 1572-1580 (2015).

Terms in the title (7)： オキシブチニン塩酸塩 ,  血中濃度 ,  分析 ,  マウス ,  オキシブチニン ,  経皮パッチ ,  併用